Industry News
Mesoblast insists Teva partnership is strong
Mesoblast (ASX:MSB) has defended the strength of its relationship with key partner Teva Pharmaceutical Industries, calling rumors that Teva is not committed to the tie-up “unfounded.” [ + ]
Immuron raises $442k in undersubscribed SPP
Immuron (ASX:IMC) has raised just over $442,000 in a share purchase plan (SPP), less than half of the $1 million target. [ + ]
R&D Tax Incentive attracts MS clinical trial
New Zealand-based Innate Immunotherapeutics has announced the company will proceed with plans to conduct a Phase IIB clinical trial in Australia, after positive interim data from the company’s Phase I/II clinical trial of MIS416 in patients with chronic progressive multiple sclerosis (MS). [ + ]
International Nanomedicine Conference bound for Sydney
The Australian Centre for Nanomedicine at the University of New South Wales will host the third International Nanomedicine Conference from 2-4 July at the Crowne Plaza Coogee Beach, Sydney. [ + ]
BIO 2012: Australian biotechnology’s time to shine
The second wave of Australian biotechnology companies is on the cusp of breaking out, but a new phenomenon is emerging in the life sciences industry: a three-tier economy. [ + ]
CSIRO’s WLAN technology wins international award
Australian science has been recognised as among the world’s best after the Minister for Science and Research, Senator Chris Evans, announced that the CSIRO inventors behind the WLAN technology have won the European Inventors Award. [ + ]
Magnetic resonance imaging pioneer honoured
UniQuest has congratulated The University of Queensland’s (UQ) Professor Stuart Crozier on receiving a 2012 Academy of Technology and Engineering Sciences (ATSE) Clunies Ross Award for his 20-year commitment to the field of magnetic resonance imaging (MRI). [ + ]
The Australian Innovation Challenge hunts for the nation’s best ideas
The search is on again for the nation’s greatest ideas - in fields from environmental science to education - through the $70,000 The Australian Innovation Challenge awards. [ + ]
Bionomics ends MS collaboration with Merck Serono
Bionomics (ASX:BNO) will cease collaborating with Merck Serono to develop autoimmune disorder treatments, and seek alternate partners for its Kv1.3 program. [ + ]
What the Raising the Bar research exemption means for biotech
The research exemption in the new Raising the Bar bill allows experimentation on patented processes, but the line between what is permitted and what is infringing a patent is not yet fully clear. [ + ]
PIC reports to Ministers on treatment of similar biologics
The Pharmaceuticals Industry Council (PIC), with members AusBiotech, Medicines Australia and the GMiA, has reported to the Federal Government on the preferred treatment of follow-on biologics for reimbursement. [ + ]
ResMed launches sleep apnoea device in US
ResMed (ASX:RMD) has brought Narval CC, an alternative treatment to PAP therapy for snoring and sleep apnoea, to the US market. [ + ]
Opinion: The brutal truth about innovation in Australia
Dr Rowan Gilmore, CEO of the Australian Institute for Commercialisation, wonders whether Australian government and business are truly hungry enough to drive innovation in this country. [ + ]
Using the cane toad’s poison against itself
An effective new weapon in the fight against the spread of cane toads has been developed by the University of Sydney, in collaboration with the University of Queensland. [ + ]
CSL gets orphan drug status for haemophilia-B treatment
CSL's (ASX:CSL) plasma protein unit, CSL Behring, has received US FDA orphan drug designation for a haemophilia-B treatment, rIX-FP. [ + ]
